New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

Instil Bio

Contributing Author

Recent Articles by Instil Bio

Mar-27	Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update TIL -6.82% GlobeNewswire
Jan-06	Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco TIL -45.81% GlobeNewswire
Nov-13	Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update TIL -7.20% GlobeNewswire
Sep-10	Instil Bio Announces ImmuneOnco's Presentation of '2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC) TIL -9.81% GlobeNewswire
Aug-13	Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update TIL GlobeNewswire
Jul-31	ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China TIL -11.14% GlobeNewswire
Jul-02	Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors TIL +8.57% GlobeNewswire
Jun-11	Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program TIL GlobeNewswire
Jun-02	Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer TIL +10.02% GlobeNewswire
May-30	Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference TIL -11.20% GlobeNewswire
May-23	Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago TIL -14.59% GlobeNewswire
May-22	Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 ('2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025 TIL +51.73% GlobeNewswire
May-13	Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update TIL -6.87% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)